{
    "clinical_study": {
        "@rank": "92521", 
        "arm_group": {
            "arm_group_label": "Observation", 
            "description": "Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole"
        }, 
        "biospec_descr": {
            "textblock": "Whole blood, Plasma"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects\n      with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are\n      currently on treatment with oral aripiprazole."
        }, 
        "brief_title": "Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Bipolar 1 Disorder", 
            "Schizophrenia", 
            "Mental Disorder", 
            "Nervous System Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Nervous System Diseases", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects\n      with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are\n      currently on treatment with oral aripiprazole. This will be an open-label observational\n      pilot trial to compare the PK profile of aripiprazole at Visit 1 of subjects who are\n      receiving oral aripiprazole and who have the potential for suboptimal adherent behavior with\n      their assigned medication.\n\n      Information obtained in the current trial will be used to inform the conduct of a\n      randomized, open-label, parallel-group trial to assess between-group change from baseline\n      adherence using PK sampling in subjects receiving oral aripiprazole with or without the\n      MIND1 System (Protocol 316-13-211)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects 18 to 55 years of age (inclusive) at time of informed\n             consent\n\n          -  Subjects with a primary current Axis 1 disorder of bipolar 1 disorder or\n             schizophrenia as defined by DSM-IV-TR criteria, who have been treated in the\n             outpatient setting for at least 2 months before screening\n\n          -  Subjects with a score of 1-7 on the Morisky 8-Item Medication Adherence Scale\n             (MMAS-8)\n\n          -  Subjects with bipolar 1 disorder who have a YMRS score of 10 to 25 (inclusive), or\n             subjects with schizophrenia who have a PANSS score of 60 to 90 (inclusive)\n\n          -  Subjects able to ingest oral medication\n\n          -  Subjects currently prescribed oral aripiprazole for either bipolar 1 disorder or\n             schizophrenia, and who have not had any changes in their Aripiprazole regimen or dose\n             over the last 2 weeks\n\n          -  Subjects who have an exacerbation of mood or psychotic symptoms when they are not\n             receiving treatment or are noncompliant with treatment for their bipolar 1 disorder\n             or schizophrenia\n\n          -  For subjects enrolled with bipolar 1 disorder, the current bipolar episode is mixed\n             or manic (the current must not be a depressive episode)\n\n        Exclusion Criteria:\n\n          -  Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar 1 disorder or\n             schizophrenia\n\n          -  Subjects with a current Axis II (DSM-IV-TR) diagnosis\n\n          -  Subjects not able to self-administer their medication\n\n          -  Subjects who reside in or attend a facility where medication is administered to them\n\n          -  Subjects who have a score of 0 or 8 on the Morisky 8-Item Medication Adherence Scale\n             (MMAS-8)\n\n          -  Subjects who currently meet DSM-IV-TR criteria for substance dependence\n\n          -  Subjects with a history of inpatient hospitalization for any psychiatric reason\n             within the past 2 months before screening\n\n          -  Subjects who have received any investigational product within the last 30 days\n\n          -  Subjects known to be allergic, intolerant, or unresponsive to prior treatment with\n             Aripiprazole or other quinolinones\n\n          -  Subjects who, per investigator's judgment, are acutely psychotic or manic and/or\n             exhibit symptoms currently requiring hospitalization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic"
            }
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050854", 
            "org_study_id": "316-13-212"
        }, 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Aripiprazole", 
            "Treatment Adherence"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole", 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
            "last_name": "Kimberly Largay, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean log transformed-area under the plasma concentration-time curve (AUC) at Visit 1 for subjects receiving oral aripiprazole, compared to historical values", 
            "safety_issue": "No", 
            "time_frame": "Visit 1 (Day 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050854"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Potential relationships between a clinically accepted indicator of non-adherent behavior, the Morisky 8-item Medication Adherence scale (MMAS-8), and aripiprazole concentrations in subjects", 
            "safety_issue": "No", 
            "time_frame": "Visit 1 (Day 1) to End of Study"
        }, 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}